Fundies.
English

Segment disclosures

Company overview

Johnson & Johnson

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

447 dimension combinations 794 retained observations 4 reported periods Partial retained history

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Operating Segments · Innovative Medicine

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2816384000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2831810000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-03-2915426000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-2860401000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

Operating Segments · Med Tech

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-288926000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2817562000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-03-298636000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-2833792000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

Abiomed · US · Cardiovascular · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:AbiomedMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:CardiovascularMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2024-12-30 – 2025-12-281393000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

Abiomed · Non Us · Cardiovascular · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:AbiomedMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2024-12-30 – 2025-12-28358000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

Abiomed · Cardiovascular · Med Tech

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:AbiomedMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2024-12-30 – 2025-12-281751000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

ADVANCED · US · Surgery · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:ADVANCEDMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29477000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-281900000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

ADVANCED · Non Us · Surgery · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:ADVANCEDMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29646000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-282678000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

ADVANCED · Med Tech · Surgery

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:ADVANCEDMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281189000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282312000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

ADVANCED · Surgery · Med Tech

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:ADVANCEDMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291123000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-284577000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

CAPLYTA · US · Neuroscience · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CAPLYTAMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29270000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-28700000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

CAPLYTA · Non Us · Neuroscience · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CAPLYTAMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-290 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-280 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

CAPLYTA · Innovative Medicine · Neuroscience

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:CAPLYTAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28361000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28631000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

CAPLYTA · Neuroscience · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CAPLYTAMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29270000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-28700000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

CARVYKTI · US · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CARVYKTIMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29433000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-281492000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

CARVYKTI · Non Us · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CARVYKTIMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29164000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-28395000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

CARVYKTI · Innovative Medicine · Oncology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:CARVYKTIMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28657000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281254000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

CARVYKTI · Oncology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CARVYKTIMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29597000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence
2024-12-30 – 2025-12-281887000000 USD2026-02-11 · 21:06:11.000ZOpen filing evidence

CONCERTA Methylphenidate · US · Neuroscience · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CONCERTAMethylphenidateMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2922000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

CONCERTA Methylphenidate · Non Us · Neuroscience · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CONCERTAMethylphenidateMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29115000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

CONCERTA Methylphenidate · Innovative Medicine · Neuroscience

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:CONCERTAMethylphenidateMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28146000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28282000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

CONCERTA Methylphenidate · Neuroscience · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CONCERTAMethylphenidateMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29136000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

CONTACTLENSESOTHER · US · Vision · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CONTACTLENSESOTHERMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:VisionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29468000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

CONTACTLENSESOTHER · Non Us · Vision · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CONTACTLENSESOTHERMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:VisionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29501000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

CONTACTLENSESOTHER · Med Tech · Vision

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:CONTACTLENSESOTHERMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281025000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281994000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

CONTACTLENSESOTHER · Vision · Med Tech

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:CONTACTLENSESOTHERMember;us-gaap:SubsegmentsAxis=jnj:VisionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29969000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

DARZALEX · US · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:DARZALEXMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-292208000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

DARZALEX · Non Us · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:DARZALEXMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291756000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

DARZALEX · Innovative Medicine · Oncology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:DARZALEXMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-284207000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-288171000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

DARZALEX · Oncology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:DARZALEXMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-293964000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

EDURAN Trilpivirine · US · Infectious Diseases · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:EDURANTrilpivirineMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-297000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

EDURAN Trilpivirine · Non Us · Infectious Diseases · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:EDURANTrilpivirineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29402000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

EDURAN Trilpivirine · Innovative Medicine · Infectious Diseases

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:EDURANTrilpivirineMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28350000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28759000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

EDURAN Trilpivirine · Infectious Diseases · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:EDURANTrilpivirineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29409000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

ERLEADA · US · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:ERLEADAMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29342000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

ERLEADA · Non Us · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:ERLEADAMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29607000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

ERLEADA · Innovative Medicine · Oncology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:ERLEADAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28995000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281944000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

ERLEADA · Oncology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:ERLEADAMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29949000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

GENERAL · US · Surgery · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:GENERALMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29569000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

GENERAL · Non Us · Surgery · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:GENERALMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29819000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

GENERAL · Med Tech · Surgery

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:GENERALMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281464000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282852000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

GENERAL · Surgery · Med Tech

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:GENERALMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291388000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

HIPS · US · Orthopaedics · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:HIPSMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29277000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

HIPS · Non Us · Orthopaedics · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:HIPSMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29159000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

HIPS · Med Tech · Orthopaedics

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:HIPSMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28441000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28877000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

HIPS · Orthopaedics · Med Tech

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:HIPSMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29436000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

IMBRUVICA · US · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:IMBRUVICAMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29143000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

IMBRUVICA · Non Us · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:IMBRUVICAMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29517000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

IMBRUVICA · Innovative Medicine · Oncology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:IMBRUVICAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28599000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281259000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

IMBRUVICA · Oncology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:IMBRUVICAMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29660000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

INVEGASUSTENNAXEPLIONTRINZATREVICTA · US · Neuroscience · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29758000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

INVEGASUSTENNAXEPLIONTRINZATREVICTA · Non Us · Neuroscience · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29280000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

INVEGASUSTENNAXEPLIONTRINZATREVICTA · Innovative Medicine · Neuroscience

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281015000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282053000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

INVEGASUSTENNAXEPLIONTRINZATREVICTA · Neuroscience · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291038000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

KNEES · US · Orthopaedics · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:KNEESMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29239000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

KNEES · Non Us · Orthopaedics · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:KNEESMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29181000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

KNEES · Med Tech · Orthopaedics

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:KNEESMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28410000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28830000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

KNEES · Orthopaedics · Med Tech

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:KNEESMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29420000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

OPSUMITOPSYNVI · US · Pulmonary Hypertension · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OPSUMITOPSYNVIMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29433000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

OPSUMITOPSYNVI · Non Us · Pulmonary Hypertension · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OPSUMITOPSYNVIMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29172000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

OPSUMITOPSYNVI · Innovative Medicine · Pulmonary Hypertension

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:OPSUMITOPSYNVIMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28602000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281208000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

OPSUMITOPSYNVI · Pulmonary Hypertension · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OPSUMITOPSYNVIMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29606000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other Immunology · US · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherImmunologyMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2938000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other Immunology · Non Us · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherImmunologyMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-299000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other Immunology · Innovative Medicine · Immunology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28104000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28150000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Other Immunology · Immunology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherImmunologyMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2946000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other Infectious Diseases · US · Infectious Diseases · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherInfectiousDiseasesMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other Infectious Diseases · Non Us · Infectious Diseases · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherInfectiousDiseasesMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2936000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other Infectious Diseases · Innovative Medicine · Infectious Diseases

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherInfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2841000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2878000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Other Infectious Diseases · Infectious Diseases · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherInfectiousDiseasesMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2937000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other · US · Cardiovascular Metabolism Other · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2991000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other · US · Pulmonary Hypertension · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2912000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other · US · Total PHIDCVM · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:TotalPHIDCVMMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291907000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other · Non Us · Cardiovascular Metabolism Other · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29142000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other · Non Us · Pulmonary Hypertension · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2934000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other · Non Us · Total PHIDCVM · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:TotalPHIDCVMMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29993000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other · Innovative Medicine · Cardiovascular Metabolism Other

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28225000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28458000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Other · Innovative Medicine · Pulmonary Hypertension

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2847000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2893000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Other · Innovative Medicine · Total PHIDCVM

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:TotalPHIDCVMMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-282795000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-285694000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Other · Cardiovascular Metabolism Other · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29233000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other · Pulmonary Hypertension · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2946000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other · Total PHIDCVM · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:TotalPHIDCVMMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-292899000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

OTHERNEUROSCIENCE · US · Neuroscience · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OTHERNEUROSCIENCEMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2938000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

OTHERNEUROSCIENCE · Non Us · Neuroscience · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OTHERNEUROSCIENCEMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29224000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

OTHERNEUROSCIENCE · Innovative Medicine · Neuroscience

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:OTHERNEUROSCIENCEMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28232000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28494000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

OTHERNEUROSCIENCE · Neuroscience · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OTHERNEUROSCIENCEMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29262000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other Oncology · US · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherOncologyMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2985000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other Oncology · Non Us · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherOncologyMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29106000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Other Oncology · Innovative Medicine · Oncology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherOncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28226000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28418000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Other Oncology · Oncology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:OtherOncologyMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29192000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

PREZISTAPREZCOBIXREZOLSTASYMTUZA · US · Infectious Diseases · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29334000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

PREZISTAPREZCOBIXREZOLSTASYMTUZA · Non Us · Infectious Diseases · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29109000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

PREZISTAPREZCOBIXREZOLSTASYMTUZA · Innovative Medicine · Infectious Diseases

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28372000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28815000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

PREZISTAPREZCOBIXREZOLSTASYMTUZA · Infectious Diseases · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29443000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Remicade · US · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:RemicadeMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29269000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Remicade · UNITEDSTATES Exports · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:RemicadeMember;srt:StatementGeographicalAxis=jnj:UNITEDSTATESExportsMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2918000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Remicade · Non Us · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:RemicadeMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29136000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Remicade · Innovative Medicine · Immunology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:RemicadeMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28338000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28760000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Remicade · Immunology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:RemicadeMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29422000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

RYBREVANTLAZCLUZE · US · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:RYBREVANTLAZCLUZEMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29175000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

RYBREVANTLAZCLUZE · Non Us · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:RYBREVANTLAZCLUZEMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2982000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

RYBREVANTLAZCLUZE · Innovative Medicine · Oncology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:RYBREVANTLAZCLUZEMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28289000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28546000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

RYBREVANTLAZCLUZE · Oncology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:RYBREVANTLAZCLUZEMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29257000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Simponi Simponi Aria · US · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SimponiSimponiAriaMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29269000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Simponi Simponi Aria · Non Us · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SimponiSimponiAriaMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29378000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Simponi Simponi Aria · Innovative Medicine · Immunology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:SimponiSimponiAriaMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28618000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281265000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Simponi Simponi Aria · Immunology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SimponiSimponiAriaMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29647000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

SPINEOTHER · US · Orthopaedics · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SPINEOTHERMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29387000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

SPINEOTHER · Non Us · Orthopaedics · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SPINEOTHERMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29307000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

SPINEOTHER · Med Tech · Orthopaedics

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:SPINEOTHERMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28740000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281434000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

SPINEOTHER · Orthopaedics · Med Tech

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SPINEOTHERMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29694000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

SPRAVATO · US · Neuroscience · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SPRAVATOMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29406000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

SPRAVATO · Non Us · Neuroscience · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SPRAVATOMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2961000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

SPRAVATO · Innovative Medicine · Neuroscience

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:SPRAVATOMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28584000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281052000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

SPRAVATO · Neuroscience · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SPRAVATOMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29468000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Stelara · US · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:StelaraMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29220000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Stelara · Non Us · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:StelaraMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29435000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Stelara · Innovative Medicine · Immunology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:StelaraMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28740000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281396000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Stelara · Immunology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:StelaraMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29656000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

SURGICAL · US · Vision · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SURGICALMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:VisionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29111000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

SURGICAL · Non Us · Vision · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SURGICALMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:VisionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29285000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

SURGICAL · Med Tech · Vision

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:SURGICALMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28426000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28822000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

SURGICAL · Vision · Med Tech

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:SURGICALMember;us-gaap:SubsegmentsAxis=jnj:VisionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29396000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

TALVEY · US · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TALVEYMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29101000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

TALVEY · Non Us · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TALVEYMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2951000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

TALVEY · Innovative Medicine · Oncology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:TALVEYMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28174000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28326000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

TALVEY · Oncology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TALVEYMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29152000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Tecvayli · US · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TecvayliMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29127000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Tecvayli · Non Us · Oncology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TecvayliMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2974000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Tecvayli · Innovative Medicine · Oncology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:TecvayliMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28260000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28462000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Tecvayli · Oncology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TecvayliMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29202000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

TRAUMA · US · Orthopaedics · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TRAUMAMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29532000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

TRAUMA · Non Us · Orthopaedics · Med Tech

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TRAUMAMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29301000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

TRAUMA · Med Tech · Orthopaedics

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:TRAUMAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28827000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281660000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

TRAUMA · Orthopaedics · Med Tech

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TRAUMAMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29833000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Tremfya · US · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TremfyaMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291042000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Tremfya · Non Us · Immunology · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TremfyaMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29566000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Tremfya · Innovative Medicine · Immunology

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:TremfyaMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-282046000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-283654000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Tremfya · Immunology · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:TremfyaMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291608000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

UPTRAVI · US · Pulmonary Hypertension · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:UPTRAVIMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29385000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

UPTRAVI · Non Us · Pulmonary Hypertension · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:UPTRAVIMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2998000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

UPTRAVI · Innovative Medicine · Pulmonary Hypertension

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:UPTRAVIMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28494000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28977000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

UPTRAVI · Pulmonary Hypertension · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:UPTRAVIMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29483000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Xarelto · US · Cardiovascular Metabolism Other · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:XareltoMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29642000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Xarelto · Non Us · Cardiovascular Metabolism Other · Innovative Medicine

Product Or Service · Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:XareltoMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-290 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Xarelto · Innovative Medicine · Cardiovascular Metabolism Other

Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:ProductOrServiceAxis=jnj:XareltoMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28664000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281306000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Xarelto · Cardiovascular Metabolism Other · Innovative Medicine

Product Or Service · Subsegments · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=jnj:XareltoMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29642000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · ADVANCED · Med Tech · Surgery

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:ADVANCEDMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28499000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28976000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · CAPLYTA · Innovative Medicine · Neuroscience

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:CAPLYTAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28361000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28631000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · CARVYKTI · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:CARVYKTIMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28472000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28905000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · CONCERTA Methylphenidate · Innovative Medicine · Neuroscience

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:CONCERTAMethylphenidateMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2812000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2834000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · CONTACTLENSESOTHER · Med Tech · Vision

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:CONTACTLENSESOTHERMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28445000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28913000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · DARZALEX · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:DARZALEXMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-282435000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-284643000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · EDURAN Trilpivirine · Innovative Medicine · Infectious Diseases

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:EDURANTrilpivirineMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-283000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2810000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · ERLEADA · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:ERLEADAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28396000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28738000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · GENERAL · Med Tech · Surgery

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:GENERALMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28596000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281165000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · HIPS · Med Tech · Orthopaedics

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:HIPSMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28283000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28560000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · IMBRUVICA · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:IMBRUVICAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28149000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28292000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · INVEGASUSTENNAXEPLIONTRINZATREVICTA · Innovative Medicine · Neuroscience

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28738000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281496000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · KNEES · Med Tech · Orthopaedics

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:KNEESMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28228000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28467000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · OPSUMITOPSYNVI · Innovative Medicine · Pulmonary Hypertension

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OPSUMITOPSYNVIMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28416000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28849000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Other Immunology · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2885000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28123000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Other Infectious Diseases · Innovative Medicine · Infectious Diseases

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherInfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Other · Innovative Medicine · Cardiovascular Metabolism Other

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28101000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28192000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Other · Innovative Medicine · Pulmonary Hypertension

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2813000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2825000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Other · Innovative Medicine · Total PHIDCVM

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:TotalPHIDCVMMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281878000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-283785000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · OTHERNEUROSCIENCE · Innovative Medicine · Neuroscience

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OTHERNEUROSCIENCEMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2834000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2872000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Other Oncology · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherOncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28131000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28216000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · PREZISTAPREZCOBIXREZOLSTASYMTUZA · Innovative Medicine · Infectious Diseases

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28296000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28630000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Remicade · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:RemicadeMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28215000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28484000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · RYBREVANTLAZCLUZE · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:RYBREVANTLAZCLUZEMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28190000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28365000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Simponi Simponi Aria · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:SimponiSimponiAriaMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28260000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28529000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · SPINEOTHER · Med Tech · Orthopaedics

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:SPINEOTHERMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28423000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28810000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · SPRAVATO · Innovative Medicine · Neuroscience

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:SPRAVATOMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28514000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28920000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Stelara · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:StelaraMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28336000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28556000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · SURGICAL · Med Tech · Vision

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:SURGICALMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28120000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28231000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · TALVEY · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:TALVEYMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28112000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28213000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Tecvayli · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:TecvayliMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28186000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28313000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · TRAUMA · Med Tech · Orthopaedics

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:TRAUMAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28536000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281068000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Tremfya · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:TremfyaMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281465000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282507000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · UPTRAVI · Innovative Medicine · Pulmonary Hypertension

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:UPTRAVIMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28386000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28771000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Xarelto · Innovative Medicine · Cardiovascular Metabolism Other

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:XareltoMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28664000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281306000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Innovative Medicine

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-289979000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2818850000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-03-298871000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Innovative Medicine · Cardiovascular Metabolism Other

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28765000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281499000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Innovative Medicine · Immunology

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-282372000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-284227000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Innovative Medicine · Infectious Diseases

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28300000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28642000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Innovative Medicine · Neuroscience

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281659000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-283153000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Innovative Medicine · Oncology

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-284069000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-287684000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Innovative Medicine · Pulmonary Hypertension

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28814000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281645000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Med Tech

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-284554000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-289013000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-03-294459000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Med Tech · Abiomed

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:AbiomedMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28342000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28731000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Med Tech · Cardiovascular

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281426000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282825000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Med Tech · Electrophysiology

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:ElectrophysiologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28783000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281519000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Med Tech · Orthopaedics

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281470000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282905000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Med Tech · Other Cardiovascular

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OtherCardiovascularMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2833000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2865000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Med Tech · Shockwave

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:ShockwaveMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28268000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28510000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Med Tech · Surgery

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281094000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282140000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Med Tech · Vision

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28565000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281144000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

US · Abiomed · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:AbiomedMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29389000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Cardiovascular · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:CardiovascularMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291399000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Cardiovascular Metabolism Other · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29734000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Electrophysiology · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ElectrophysiologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29736000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Immunology · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291855000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Infectious Diseases · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29342000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Neuroscience · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291494000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Oncology · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-293615000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Orthopaedics · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291435000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Other Cardiovascular · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OtherCardiovascularMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2932000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Pulmonary Hypertension · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29831000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Shockwave · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ShockwaveMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29242000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Surgery · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291046000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

US · Vision · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:VisionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29579000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

UNITEDSTATES Exports · Remicade · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=jnj:UNITEDSTATESExportsMember;srt:ProductOrServiceAxis=jnj:RemicadeMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2810000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2828000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · ADVANCED · Med Tech · Surgery

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:ADVANCEDMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28691000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281337000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · CAPLYTA · Innovative Medicine · Neuroscience

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:CAPLYTAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-280 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-280 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · CARVYKTI · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:CARVYKTIMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28185000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28349000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · CONCERTA Methylphenidate · Innovative Medicine · Neuroscience

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:CONCERTAMethylphenidateMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28133000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28248000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · CONTACTLENSESOTHER · Med Tech · Vision

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:CONTACTLENSESOTHERMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28580000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281081000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · DARZALEX · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:DARZALEXMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281772000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-283528000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · EDURAN Trilpivirine · Innovative Medicine · Infectious Diseases

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:EDURANTrilpivirineMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28347000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28749000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · ERLEADA · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:ERLEADAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28599000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281206000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · GENERAL · Med Tech · Surgery

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:GENERALMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28868000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281687000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · HIPS · Med Tech · Orthopaedics

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:HIPSMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28158000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28317000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · IMBRUVICA · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:IMBRUVICAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28449000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28966000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · INVEGASUSTENNAXEPLIONTRINZATREVICTA · Innovative Medicine · Neuroscience

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28278000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28558000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · KNEES · Med Tech · Orthopaedics

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:KNEESMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28182000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28363000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · OPSUMITOPSYNVI · Innovative Medicine · Pulmonary Hypertension

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OPSUMITOPSYNVIMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28187000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28359000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Other Immunology · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2818000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2827000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Other Infectious Diseases · Innovative Medicine · Infectious Diseases

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherInfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2840000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2876000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Other · Innovative Medicine · Cardiovascular Metabolism Other

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28124000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28266000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Other · Innovative Medicine · Pulmonary Hypertension

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2834000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2868000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Other · Innovative Medicine · Total PHIDCVM

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:TotalPHIDCVMMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28916000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281909000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · OTHERNEUROSCIENCE · Innovative Medicine · Neuroscience

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OTHERNEUROSCIENCEMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28198000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28422000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Other Oncology · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherOncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2897000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28203000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · PREZISTAPREZCOBIXREZOLSTASYMTUZA · Innovative Medicine · Infectious Diseases

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2876000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28185000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Remicade · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:RemicadeMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28112000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28248000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · RYBREVANTLAZCLUZE · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:RYBREVANTLAZCLUZEMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2899000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28181000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Simponi Simponi Aria · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:SimponiSimponiAriaMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28358000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28736000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · SPINEOTHER · Med Tech · Orthopaedics

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:SPINEOTHERMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28317000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28624000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · SPRAVATO · Innovative Medicine · Neuroscience

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:SPRAVATOMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2870000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28131000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Stelara · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:StelaraMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28404000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28839000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · SURGICAL · Med Tech · Vision

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:SURGICALMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28306000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28591000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · TALVEY · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:TALVEYMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2862000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28113000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Tecvayli · Innovative Medicine · Oncology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:TecvayliMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2874000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28148000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · TRAUMA · Med Tech · Orthopaedics

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:TRAUMAMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28291000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28592000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Tremfya · Innovative Medicine · Immunology

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:TremfyaMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28581000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281147000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · UPTRAVI · Innovative Medicine · Pulmonary Hypertension

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:UPTRAVIMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28108000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28206000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Xarelto · Innovative Medicine · Cardiovascular Metabolism Other

Statement Geographical · Product Or Service · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:XareltoMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-280 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-280 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Innovative Medicine

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-286405000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2812960000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-03-296555000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Innovative Medicine · Cardiovascular Metabolism Other

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28124000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28266000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Innovative Medicine · Immunology

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281473000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282997000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Innovative Medicine · Infectious Diseases

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28463000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281010000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Innovative Medicine · Neuroscience

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28678000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281359000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Innovative Medicine · Oncology

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-283337000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-286695000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Innovative Medicine · Pulmonary Hypertension

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28329000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28633000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Med Tech

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-284372000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-288549000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-03-294177000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Med Tech · Abiomed

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:AbiomedMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2897000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28197000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Med Tech · Cardiovascular

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28978000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281956000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Med Tech · Electrophysiology

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:ElectrophysiologyMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28749000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281502000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Med Tech · Orthopaedics

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28948000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281896000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Med Tech · Other Cardiovascular

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OtherCardiovascularMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2865000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28127000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Med Tech · Shockwave

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:ShockwaveMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2867000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28130000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Med Tech · Surgery

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281559000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-283024000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Med Tech · Vision

Statement Geographical · Statement Business Segments · Subsegments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28887000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281672000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Non Us · Abiomed · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:AbiomedMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29100000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Cardiovascular · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29978000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Cardiovascular Metabolism Other · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29142000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Electrophysiology · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ElectrophysiologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29753000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Immunology · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291524000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Infectious Diseases · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29547000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Neuroscience · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29681000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Oncology · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-293358000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Orthopaedics · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29948000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Other Cardiovascular · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OtherCardiovascularMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2962000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Pulmonary Hypertension · Innovative Medicine

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29304000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Shockwave · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ShockwaveMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-2963000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Surgery · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-291465000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Non Us · Vision · Med Tech

Statement Geographical · Subsegments · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:VisionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2025-12-29 – 2026-03-29785000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Innovative Medicine

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2716757000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2748567000000 USD20261021Open filing evidence
2026-03-30 – 2026-06-2816384000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2831810000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-03-2915426000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Innovative Medicine · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2716757000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2748567000000 USD20261021Open filing evidence

Innovative Medicine · CAPLYTA · Neuroscience

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:CAPLYTAMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27398000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271029000000 USD20261021Open filing evidence

Innovative Medicine · CARVYKTI · Oncology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:CARVYKTIMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27710000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271964000000 USD20261021Open filing evidence

Innovative Medicine · CONCERTA Methylphenidate · Neuroscience

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:CONCERTAMethylphenidateMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27143000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27425000000 USD20261021Open filing evidence

Innovative Medicine · DARZALEX · Oncology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:DARZALEXMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-274239000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2712410000000 USD20261021Open filing evidence

Innovative Medicine · EDURAN Trilpivirine · Infectious Diseases

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:EDURANTrilpivirineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27386000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271145000000 USD20261021Open filing evidence

Innovative Medicine · ERLEADA · Oncology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:ERLEADAMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271023000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272967000000 USD20261021Open filing evidence

Innovative Medicine · IMBRUVICA · Oncology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:IMBRUVICAMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27563000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271822000000 USD20261021Open filing evidence

Innovative Medicine · INVEGASUSTENNAXEPLIONTRINZATREVICTA · Neuroscience

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27998000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-273051000000 USD20261021Open filing evidence

Innovative Medicine · OPSUMITOPSYNVI · Pulmonary Hypertension

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:OPSUMITOPSYNVIMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27372000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271580000000 USD20261021Open filing evidence

Innovative Medicine · Other Immunology · Immunology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:OtherImmunologyMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27147000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27297000000 USD20261021Open filing evidence

Innovative Medicine · Other Infectious Diseases · Infectious Diseases

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:OtherInfectiousDiseasesMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2746000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27124000000 USD20261021Open filing evidence

Innovative Medicine · Other · Cardiovascular Metabolism Other

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27197000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27655000000 USD20261021Open filing evidence

Innovative Medicine · Other · Pulmonary Hypertension

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2742000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27135000000 USD20261021Open filing evidence

Innovative Medicine · Other · Total PHIDCVM

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:TotalPHIDCVMMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-272560000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-278254000000 USD20261021Open filing evidence

Innovative Medicine · OTHERNEUROSCIENCE · Neuroscience

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:OTHERNEUROSCIENCEMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27212000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27706000000 USD20261021Open filing evidence

Innovative Medicine · Other Oncology · Oncology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:OtherOncologyMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27262000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27680000000 USD20261021Open filing evidence

Innovative Medicine · PREZISTAPREZCOBIXREZOLSTASYMTUZA · Infectious Diseases

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27381000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271196000000 USD20261021Open filing evidence

Innovative Medicine · Remicade · Immunology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:RemicadeMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27394000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271154000000 USD20261021Open filing evidence

Innovative Medicine · RYBREVANTLAZCLUZE · Oncology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:RYBREVANTLAZCLUZEMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27320000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27866000000 USD20261021Open filing evidence

Innovative Medicine · Simponi Simponi Aria · Immunology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:SimponiSimponiAriaMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27568000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271833000000 USD20261021Open filing evidence

Innovative Medicine · SPRAVATO · Neuroscience

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:SPRAVATOMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27624000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271676000000 USD20261021Open filing evidence

Innovative Medicine · Stelara · Immunology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:StelaraMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27716000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272112000000 USD20261021Open filing evidence

Innovative Medicine · TALVEY · Oncology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:TALVEYMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27171000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27497000000 USD20261021Open filing evidence

Innovative Medicine · Tecvayli · Oncology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:TecvayliMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27312000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27774000000 USD20261021Open filing evidence

Innovative Medicine · Tremfya · Immunology

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:TremfyaMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-272396000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-276050000000 USD20261021Open filing evidence

Innovative Medicine · UPTRAVI · Pulmonary Hypertension

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:UPTRAVIMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27483000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271460000000 USD20261021Open filing evidence

Innovative Medicine · Xarelto · Cardiovascular Metabolism Other

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:ProductOrServiceAxis=jnj:XareltoMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27653000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271959000000 USD20261021Open filing evidence

Innovative Medicine · US

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2710447000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2729297000000 USD20261021Open filing evidence

Innovative Medicine · US · CAPLYTA · Neuroscience

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:CAPLYTAMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27398000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271029000000 USD20261021Open filing evidence

Innovative Medicine · US · CARVYKTI · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:CARVYKTIMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27472000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271377000000 USD20261021Open filing evidence

Innovative Medicine · US · CONCERTA Methylphenidate · Neuroscience

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:CONCERTAMethylphenidateMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-276000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2740000000 USD20261021Open filing evidence

Innovative Medicine · US · DARZALEX · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:DARZALEXMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-272528000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-277171000000 USD20261021Open filing evidence

Innovative Medicine · US · EDURAN Trilpivirine · Infectious Diseases

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:EDURANTrilpivirineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-275000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2715000000 USD20261021Open filing evidence

Innovative Medicine · US · ERLEADA · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:ERLEADAMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27423000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271161000000 USD20261021Open filing evidence

Innovative Medicine · US · IMBRUVICA · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:IMBRUVICAMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27145000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27437000000 USD20261021Open filing evidence

Innovative Medicine · US · INVEGASUSTENNAXEPLIONTRINZATREVICTA · Neuroscience

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27739000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272235000000 USD20261021Open filing evidence

Innovative Medicine · US · OPSUMITOPSYNVI · Pulmonary Hypertension

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OPSUMITOPSYNVIMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27193000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271042000000 USD20261021Open filing evidence

Innovative Medicine · US · Other Immunology · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherImmunologyMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27126000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27249000000 USD20261021Open filing evidence

Innovative Medicine · US · Other Infectious Diseases · Infectious Diseases

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherInfectiousDiseasesMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-275000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-277000000 USD20261021Open filing evidence

Innovative Medicine · US · Other · Cardiovascular Metabolism Other

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2784000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27276000000 USD20261021Open filing evidence

Innovative Medicine · US · Other · Pulmonary Hypertension

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2712000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2737000000 USD20261021Open filing evidence

Innovative Medicine · US · Other · Total PHIDCVM

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:TotalPHIDCVMMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271643000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-275428000000 USD20261021Open filing evidence

Innovative Medicine · US · OTHERNEUROSCIENCE · Neuroscience

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OTHERNEUROSCIENCEMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2732000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27104000000 USD20261021Open filing evidence

Innovative Medicine · US · Other Oncology · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:OtherOncologyMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27149000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27365000000 USD20261021Open filing evidence

Innovative Medicine · US · PREZISTAPREZCOBIXREZOLSTASYMTUZA · Infectious Diseases

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27307000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27937000000 USD20261021Open filing evidence

Innovative Medicine · US · Remicade · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:RemicadeMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27258000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27742000000 USD20261021Open filing evidence

Innovative Medicine · US · RYBREVANTLAZCLUZE · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:RYBREVANTLAZCLUZEMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27201000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27566000000 USD20261021Open filing evidence

Innovative Medicine · US · Simponi Simponi Aria · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:SimponiSimponiAriaMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27269000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27798000000 USD20261021Open filing evidence

Innovative Medicine · US · SPRAVATO · Neuroscience

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:SPRAVATOMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27559000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271479000000 USD20261021Open filing evidence

Innovative Medicine · US · Stelara · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:StelaraMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27368000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27924000000 USD20261021Open filing evidence

Innovative Medicine · US · TALVEY · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:TALVEYMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27112000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27325000000 USD20261021Open filing evidence

Innovative Medicine · US · Tecvayli · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:TecvayliMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27236000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27549000000 USD20261021Open filing evidence

Innovative Medicine · US · Tremfya · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:TremfyaMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271772000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-274279000000 USD20261021Open filing evidence

Innovative Medicine · US · UPTRAVI · Pulmonary Hypertension

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:UPTRAVIMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27383000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271154000000 USD20261021Open filing evidence

Innovative Medicine · US · Xarelto · Cardiovascular Metabolism Other

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:XareltoMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27653000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271959000000 USD20261021Open filing evidence

Innovative Medicine · US · Cardiovascular Metabolism Other

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27736000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272235000000 USD20261021Open filing evidence

Innovative Medicine · US · Immunology

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-272804000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-277031000000 USD20261021Open filing evidence

Innovative Medicine · US · Infectious Diseases

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27317000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27959000000 USD20261021Open filing evidence

Innovative Medicine · US · Neuroscience

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271733000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-274886000000 USD20261021Open filing evidence

Innovative Medicine · US · Oncology

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-274267000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2711951000000 USD20261021Open filing evidence

Innovative Medicine · US · Pulmonary Hypertension

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27588000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272233000000 USD20261021Open filing evidence

Innovative Medicine · UNITEDSTATES Exports · Remicade · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=jnj:UNITEDSTATESExportsMember;srt:ProductOrServiceAxis=jnj:RemicadeMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2712000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2740000000 USD20261021Open filing evidence

Innovative Medicine · Non Us

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-276310000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2719270000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · CAPLYTA · Neuroscience

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:CAPLYTAMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-270 USD20261021Open filing evidence
2025-12-29 – 2026-09-270 USD20261021Open filing evidence

Innovative Medicine · Non Us · CARVYKTI · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:CARVYKTIMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27238000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27587000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · CONCERTA Methylphenidate · Neuroscience

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:CONCERTAMethylphenidateMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27138000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27386000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · DARZALEX · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:DARZALEXMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271711000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-275239000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · EDURAN Trilpivirine · Infectious Diseases

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:EDURANTrilpivirineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27382000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271131000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · ERLEADA · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:ERLEADAMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27600000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271806000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · IMBRUVICA · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:IMBRUVICAMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27420000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271386000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · INVEGASUSTENNAXEPLIONTRINZATREVICTA · Neuroscience

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27258000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27816000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · OPSUMITOPSYNVI · Pulmonary Hypertension

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OPSUMITOPSYNVIMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27179000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27538000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Other Immunology · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherImmunologyMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2721000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2748000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Other Infectious Diseases · Infectious Diseases

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherInfectiousDiseasesMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2740000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27116000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Other · Cardiovascular Metabolism Other

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27112000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27378000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Other · Pulmonary Hypertension

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2730000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2798000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Other · Total PHIDCVM

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherMember;us-gaap:SubsegmentsAxis=jnj:TotalPHIDCVMMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27917000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272826000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · OTHERNEUROSCIENCE · Neuroscience

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OTHERNEUROSCIENCEMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27180000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27602000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Other Oncology · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:OtherOncologyMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27111000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27314000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · PREZISTAPREZCOBIXREZOLSTASYMTUZA · Infectious Diseases

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2774000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27259000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Remicade · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:RemicadeMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27124000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27372000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · RYBREVANTLAZCLUZE · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:RYBREVANTLAZCLUZEMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27119000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27300000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Simponi Simponi Aria · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:SimponiSimponiAriaMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27299000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271035000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · SPRAVATO · Neuroscience

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:SPRAVATOMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2766000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27197000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Stelara · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:StelaraMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27349000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271188000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · TALVEY · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:TALVEYMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2759000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27172000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Tecvayli · Oncology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:TecvayliMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2777000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27225000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Tremfya · Immunology

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:TremfyaMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27624000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271771000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · UPTRAVI · Pulmonary Hypertension

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:UPTRAVIMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27100000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27306000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Xarelto · Cardiovascular Metabolism Other

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:XareltoMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-270 USD20261021Open filing evidence
2025-12-29 – 2026-09-270 USD20261021Open filing evidence

Innovative Medicine · Non Us · Cardiovascular Metabolism Other

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27112000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27378000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Immunology

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271417000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-274414000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Infectious Diseases

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27496000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271506000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Neuroscience

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27642000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272001000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Oncology

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-273335000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2710030000000 USD20261021Open filing evidence

Innovative Medicine · Non Us · Pulmonary Hypertension

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27309000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27942000000 USD20261021Open filing evidence

Innovative Medicine · Cardiovascular Metabolism Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27849000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272614000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-29876000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Innovative Medicine · Immunology

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:ImmunologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-274221000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2711445000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-293380000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Innovative Medicine · Infectious Diseases

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27813000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272465000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-29889000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Innovative Medicine · Neuroscience

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-272375000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-276887000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-292175000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Innovative Medicine · Oncology

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:OncologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-277602000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2721981000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-296973000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Innovative Medicine · Pulmonary Hypertension

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember;us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27897000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-273175000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-291135000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Med Tech

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-278642000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2726204000000 USD20261021Open filing evidence
2026-03-30 – 2026-06-288926000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2817562000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-03-298636000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Med Tech · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-278642000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2726204000000 USD20261021Open filing evidence

Med Tech · ADVANCED · Surgery

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:ProductOrServiceAxis=jnj:ADVANCEDMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271155000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-273467000000 USD20261021Open filing evidence

Med Tech · CONTACTLENSESOTHER · Vision

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:ProductOrServiceAxis=jnj:CONTACTLENSESOTHERMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271053000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-273047000000 USD20261021Open filing evidence

Med Tech · GENERAL · Surgery

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:ProductOrServiceAxis=jnj:GENERALMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271373000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-274225000000 USD20261021Open filing evidence

Med Tech · HIPS · Orthopaedics

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:ProductOrServiceAxis=jnj:HIPSMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27419000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271296000000 USD20261021Open filing evidence

Med Tech · KNEES · Orthopaedics

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:ProductOrServiceAxis=jnj:KNEESMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27386000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271216000000 USD20261021Open filing evidence

Med Tech · SPINEOTHER · Orthopaedics

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:ProductOrServiceAxis=jnj:SPINEOTHERMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27697000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272131000000 USD20261021Open filing evidence

Med Tech · SURGICAL · Vision

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:ProductOrServiceAxis=jnj:SURGICALMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27408000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271230000000 USD20261021Open filing evidence

Med Tech · TRAUMA · Orthopaedics

Statement Business Segments · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:ProductOrServiceAxis=jnj:TRAUMAMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27844000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272504000000 USD20261021Open filing evidence

Med Tech · US

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-274512000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2713525000000 USD20261021Open filing evidence

Med Tech · US · ADVANCED · Surgery

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:ADVANCEDMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27500000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271476000000 USD20261021Open filing evidence

Med Tech · US · CONTACTLENSESOTHER · Vision

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:CONTACTLENSESOTHERMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27465000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271378000000 USD20261021Open filing evidence

Med Tech · US · GENERAL · Surgery

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:GENERALMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27568000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271733000000 USD20261021Open filing evidence

Med Tech · US · HIPS · Orthopaedics

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:HIPSMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27271000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27831000000 USD20261021Open filing evidence

Med Tech · US · KNEES · Orthopaedics

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:KNEESMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27221000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27688000000 USD20261021Open filing evidence

Med Tech · US · SPINEOTHER · Orthopaedics

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:SPINEOTHERMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27401000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271211000000 USD20261021Open filing evidence

Med Tech · US · SURGICAL · Vision

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:SURGICALMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27132000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27363000000 USD20261021Open filing evidence

Med Tech · US · TRAUMA · Orthopaedics

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=jnj:TRAUMAMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27555000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271623000000 USD20261021Open filing evidence

Med Tech · US · Abiomed

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:AbiomedMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27335000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271066000000 USD20261021Open filing evidence

Med Tech · US · Cardiovascular

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:CardiovascularMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271397000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-274222000000 USD20261021Open filing evidence

Med Tech · US · Electrophysiology

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ElectrophysiologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27771000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272290000000 USD20261021Open filing evidence

Med Tech · US · Orthopaedics

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271448000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-274353000000 USD20261021Open filing evidence

Med Tech · US · Other Cardiovascular

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:OtherCardiovascularMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2731000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2796000000 USD20261021Open filing evidence

Med Tech · US · Shockwave

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:ShockwaveMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27261000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27771000000 USD20261021Open filing evidence

Med Tech · US · Surgery

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271070000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-273210000000 USD20261021Open filing evidence

Med Tech · US · Vision

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=country:US;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27596000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271740000000 USD20261021Open filing evidence

Med Tech · Non Us

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-274130000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-2712679000000 USD20261021Open filing evidence

Med Tech · Non Us · ADVANCED · Surgery

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:ADVANCEDMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27654000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271991000000 USD20261021Open filing evidence

Med Tech · Non Us · CONTACTLENSESOTHER · Vision

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:CONTACTLENSESOTHERMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27588000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271669000000 USD20261021Open filing evidence

Med Tech · Non Us · GENERAL · Surgery

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:GENERALMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27805000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272492000000 USD20261021Open filing evidence

Med Tech · Non Us · HIPS · Orthopaedics

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:HIPSMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27148000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27465000000 USD20261021Open filing evidence

Med Tech · Non Us · KNEES · Orthopaedics

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:KNEESMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27165000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27528000000 USD20261021Open filing evidence

Med Tech · Non Us · SPINEOTHER · Orthopaedics

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:SPINEOTHERMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27296000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27920000000 USD20261021Open filing evidence

Med Tech · Non Us · SURGICAL · Vision

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:SURGICALMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27276000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27867000000 USD20261021Open filing evidence

Med Tech · Non Us · TRAUMA · Orthopaedics

Statement Business Segments · Statement Geographical · Product Or Service · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ProductOrServiceAxis=jnj:TRAUMAMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27288000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27880000000 USD20261021Open filing evidence

Med Tech · Non Us · Abiomed

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:AbiomedMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2778000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27275000000 USD20261021Open filing evidence

Med Tech · Non Us · Cardiovascular

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27910000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272866000000 USD20261021Open filing evidence

Med Tech · Non Us · Electrophysiology

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ElectrophysiologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27717000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272219000000 USD20261021Open filing evidence

Med Tech · Non Us · Orthopaedics

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27898000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272794000000 USD20261021Open filing evidence

Med Tech · Non Us · Other Cardiovascular

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:OtherCardiovascularMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2750000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27177000000 USD20261021Open filing evidence

Med Tech · Non Us · Shockwave

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:ShockwaveMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2764000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27194000000 USD20261021Open filing evidence

Med Tech · Non Us · Surgery

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271459000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-274483000000 USD20261021Open filing evidence

Med Tech · Non Us · Vision

Statement Business Segments · Statement Geographical · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27865000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-272537000000 USD20261021Open filing evidence

Med Tech · Abiomed

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:AbiomedMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27412000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-271340000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-29488000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Med Tech · Cardiovascular

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:CardiovascularMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-272307000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-277088000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-292377000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Med Tech · Electrophysiology

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:ElectrophysiologyMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271487000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-274509000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-291489000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Med Tech · Orthopaedics

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-272345000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-277146000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-292383000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Med Tech · Other Cardiovascular

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:OtherCardiovascularMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-2781000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27273000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-2994000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Med Tech · Shockwave

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:ShockwaveMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-27325000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-27965000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-29305000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Med Tech · Surgery

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:SurgeryMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-272528000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-277692000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-292511000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Med Tech · Vision

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember;us-gaap:SubsegmentsAxis=jnj:VisionMember
PeriodValueUnitFiledEvidence
2026-06-29 – 2026-09-271461000000 USD20261021Open filing evidence
2025-12-29 – 2026-09-274277000000 USD20261021Open filing evidence
2025-12-29 – 2026-03-291365000000 USD2026-04-22 · 20:02:41.000ZOpen filing evidence

Abiomed · Med Tech

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:AbiomedMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28440000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28928000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Cardiovascular · Med Tech

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:CardiovascularMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-282404000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-284781000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Cardiovascular Metabolism Other · Innovative Medicine

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:CardiovascularMetabolismOtherMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28889000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281765000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Electrophysiology · Med Tech

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:ElectrophysiologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281533000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-283022000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Immunology · Innovative Medicine

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:ImmunologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-283844000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-287224000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Infectious Diseases · Innovative Medicine

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:InfectiousDiseasesMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28763000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-281652000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Neuroscience · Innovative Medicine

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:NeuroscienceMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-282337000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-284512000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Oncology · Innovative Medicine

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-287406000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-2814379000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Orthopaedics · Med Tech

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:OrthopaedicsMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-282418000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-284801000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Other Cardiovascular · Med Tech

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:OtherCardiovascularMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-2898000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28192000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Pulmonary Hypertension · Innovative Medicine

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:PulmonaryHypertensionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:InnovativeMedicineMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281143000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282278000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Shockwave · Med Tech

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:ShockwaveMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-28335000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-28640000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Surgery · Med Tech

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-282653000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-285164000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence

Vision · Med Tech

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=jnj:VisionMember;us-gaap:StatementBusinessSegmentsAxis=jnj:MedTechMember
PeriodValueUnitFiledEvidence
2026-03-30 – 2026-06-281451000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence
2025-12-29 – 2026-06-282816000000 USD2026-07-23 · 20:04:19.000ZOpen filing evidence